News & Updates

Current thresholds of N-terminal pro–B-type natriuretic peptide (NT-proBNP) tend to underestimate the risk of adverse heart failure (HF) outcomes among individuals with higher BMI, reveals a study.

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) results in a decrease in deaths and major adverse cardiovascular events (MACE) in high-risk patients, reports as study.

Discontinuing treatment with GLP-1RAs before or early into pregnancy in women with obesity may lead to more gestational weight gain and increased risk of preterm delivery, gestational diabetes, and hypertensive disorders of pregnancy, according to a retrospective study.

The PCSK9 inhibitor evolocumab, when added to background lipid-lowering therapy, helps reduce the risk of major adverse cardiovascular events in patients with atherosclerosis or diabetes who have no history of myocardial infarction (MI) or stroke, according to the randomized VESALIUS-CV trial.

Percutaneous balloon pericardiotomy (PBP) significantly reduces recurrence of malignant pericardial effusion (MPE) by 85 percent compared with pericardiocentesis (PC), according to the randomized controlled PMAP trial conducted by a multispecialty team of researchers from the Chinese University of Hong Kong (CUHK).

A once-daily polypill containing three medications (metoprolol succinate, empagliflozin, and spironolactone) is associated with improved outcomes in patients with heart failure with reduced ejection fraction (HFrEF), according to the POLY-HF trial presented at AHA 2025.